Boston Scientific Co. (NYSE:BSX) Shares Purchased by Van ECK Associates Corp

Van ECK Associates Corp raised its holdings in Boston Scientific Co. (NYSE:BSX) by 3.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 52,405 shares of the medical equipment provider’s stock after acquiring an additional 1,659 shares during the period. Van ECK Associates Corp’s holdings in Boston Scientific were worth $3,030,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Bruce G. Allen Investments LLC purchased a new position in Boston Scientific during the fourth quarter worth about $28,000. Motco boosted its position in shares of Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 372 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 215 shares during the period. Asset Dedication LLC increased its position in Boston Scientific by 42.6% during the third quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 235 shares during the last quarter. Finally, CNB Bank purchased a new position in Boston Scientific during the third quarter worth approximately $42,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig sold 9,818 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $73.29, for a total transaction of $719,561.22. Following the sale, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Edward J. Ludwig sold 9,818 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP John Bradley Sorenson sold 17,587 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the transaction, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,620,617. The disclosure for this sale can be found here. Insiders have sold a total of 78,384 shares of company stock valued at $5,395,560 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $72.55 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The stock has a market capitalization of $106.44 billion, a price-to-earnings ratio of 60.97, a PEG ratio of 2.51 and a beta of 0.77. Boston Scientific Co. has a one year low of $48.35 and a one year high of $74.39. The company’s 50-day simple moving average is $68.54 and its 200-day simple moving average is $61.57.

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. Evercore ISI boosted their price objective on shares of Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. UBS Group upped their price target on Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Argus lifted their target price on shares of Boston Scientific from $69.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Citigroup increased their price target on Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Finally, Mizuho upped their target price on Boston Scientific from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.